2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-141154
    Amino-PEG4-Val-Cit-PAB-MMAE
    		99.93%
    Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
    Amino-PEG4-Val-Cit-PAB-MMAE
  • HY-139441
    DM21
    		99.92%
    DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936.
    DM21
  • HY-13631F
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride
    		99.89%
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research.
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride
  • HY-126687
    Mal-PEG4-VC-PAB-DMEA-PNU-159682
    Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.
    Mal-PEG4-VC-PAB-DMEA-PNU-159682
  • HY-116063
    Doxorubicin-SMCC
    		98.80%
    Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin.
    Doxorubicin-SMCC
  • HY-153892
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
    		99.79%
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is the drug-linker conjugate for ADC, containing ADC linker Gly-Mal-GGFG and ADC cytotoxin Deruxtecan 2-hydroxypropanamide.
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
  • HY-128955
    MC-VC-PABC-Aur0101
    		99.66%
    MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
    MC-VC-PABC-Aur0101
  • HY-101982
    Lys-SMCC-DM1
    		99.61%
    Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer.
    Lys-SMCC-DM1
  • HY-128904
    MC-Val-Cit-PAB-duocarmycin chloride
    		98.77%
    MC-Val-Cit-PAB-duocarmycin chloride is a agent-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-duocarmycin chloride
  • HY-153360
    MC-GGFG-AM-(10Me-11F-Camptothecin)
    		98.99%
    MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells.
    MC-GGFG-AM-(10Me-11F-Camptothecin)
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    		99.24%
    SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.
    SuO-Val-Cit-PAB-MMAE
  • HY-133433
    DBCO-PEG4-VA-PBD
    		99.68%
    DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA. DBCO-PEG4-VA-PBD is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-VA-PBD
  • HY-100874
    N3-PEG3-vc-PAB-MMAE
    		98.56%
    N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    N3-PEG3-vc-PAB-MMAE
  • HY-164239
    NH2-PEG3-VC-PAB-MMAE
    		99.10%
    NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). NH2-PEG3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    NH2-PEG3-VC-PAB-MMAE
  • HY-148057
    TCO-PEG4-VC-PAB-MMAE
    		99.30%
    TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162). TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
    TCO-PEG4-VC-PAB-MMAE
  • HY-136170
    MC-SN38
    		98.94%
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.
    MC-SN38
  • HY-148668
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM).
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan
  • HY-153795
    Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan
    		99.09%
    Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a drug-linker conjugate for ADC. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan consists of Exatecan (HY-13631) and a linker. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan can be used for synthesis of ADCs and for cancer research.
    Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan
  • HY-153032
    Val-Ala-PAB-MMAE
    		98.89%
    Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.
    Val-Ala-PAB-MMAE
  • HY-135660
    MMAE-SMCC
    		99.56%
    MMAE-SMCC is a agent-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE (HY-15162) and a linker SMCC to make antibody agent conjugate.
    MMAE-SMCC
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.